Clinical trials: Acute Depression
Major Depressive Disorder
Efficacy and Safety of Vortioxetine (Lu AA21004) in Treating Adults With Major Depressive Disorder
The purpose of this study is to determine the efficacy and safety of once daily vortioxetine (Lu AA21004) in adults with major depressive disorder.
- Trial name
- NCT00672958
- Testing
- Vortioxetine
- Where
- 33 sites in United States, Canada and 1 more
- Volunteers
- 600 people
- Sponsor
- Takeda
Acute Coronary Syndrome, Depression
Comparison of Depression Interventions After Acute Coronary Syndrome
Patients will be consented and screened within 2 to 6 months of the index ACS. Patients who have elevated depression (BDI>=15 or BDI>=10 assessed twice over two week period) and who continue to meet all of the trial's eligibility…
- Trial name
- CODIACS (NCT01032018)
- Testing
- Problem Solving Therapy, Sertraline, citalopram, or bupropion, Standard care
- Where
- 5 sites in United States
- Volunteers
- 150 people
- Sponsor
- Columbia University
Depressive Disorder, Major
Safety and Efficacy of Vortioxetine (Lu AA21004) in Adults With Major Depressive Disorder
The purpose of this study is to evaluate the efficacy, safety and tolerability of vortioxetine, once daily (QD), compared with placebo in adults with major depressive disorder.
- Trial name
- NCT01153009
- Testing
- Vortioxetine, Duloxetine
- Where
- 56 sites in United States
- Volunteers
- 614 people
- Sponsor
- Takeda
Smoking Cessation, Acute Coronary Syndrome
Post Acute Coronary Event Smoking Study
Smoking and depressed mood are both predictive of mortality following Acute Coronary Syndrome. However, to date, no counseling treatment has been designed to target smoking cessation and manage mood in this population.
- Trial name
- PACES (NCT01964898)
- Testing
- Behavioral Activation (BA), Standard Smoking Cessation Counseling, Nicotine patch
- Where
- United States
- Volunteers
- 65 people
- Sponsor
- The Miriam Hospital
Obesity, Morbid, Postoperative Pain
Study of the Effect of the Drug Gabapentin on Postoperative Pain and Incidence of Postoperative Nausea and Vomiting
The purpose of this research study is to evaluate the drug gabapentin (Neurontin®) for its ability to reduce postoperative pain, the need for morphine-like pain medication, and the severity and frequency of postoperative nausea…
- Conditions
- Obesity, Morbid, Postoperative Pain, Postoperative Nausea and Vomiting
- Trial name
- NCT00886236
- Testing
- Gabapentin
- Where
- United States
- Volunteers
- 62 people
- Sponsor
- Medical University of South Carolina
Major Depressive Disorder
Randomised Placebo-controlled Duloxetine-referenced Efficacy and Safety Study of 2.5, 5 and 10 mg of Vortioxetine (Lu AA21004) in Acute Treatment of Major Depressive Disorder
The purpose of the study is to evaluate the efficacy and the tolerability of three fixed doses of Vortioxetine in order to establish the appropriate clinical effective dose range in the treatment of Major Depressive Disorder…
- Trial name
- NCT00635219
- Testing
- Vortioxetine (Lu AA21004), Duloxetine
- Volunteers
- 766 people
- Sponsor
- H. Lundbeck A/S
Depression, Acute Pain
A Depression and Opioid Pragmatic Trial in Pharmacogenetics (DCRI Coordinating Center)
This is a Master Protocol Screening record. This study is comprised of three separate pharmacogenetic trials grouped into a single protocol due to similarities in the intervention, the hypotheses, and the trial design.
- Conditions
- Depression, Acute Pain, Chronic Pain
- Trial name
- ADOPT PGx (NCT04445792)
- Testing
- Pharmacogenetic testing, Clinical decisions support
- Where
- 14 sites in United States
- Volunteers
- 4,284 people
- Sponsor
- Duke University
Major Depressive Disorder
Efficacy Study of Vortioxetine (Lu AA21004) in Adults With Major Depressive Disorder
The purpose of this study is to determine the effectiveness and safety of vortioxetine, once daily (QD), in patients with Major Depressive Disorder.
- Trial name
- NCT00735709
- Testing
- Vortioxetine
- Where
- 48 sites in Australia, Czechia and 13 more
- Volunteers
- 560 people
- Sponsor
- Takeda
Acute Coronary Syndrome, Depression
MBCT Delivered Via Group Videoconferencing for ACS Patients With Elevated Depression Symptoms
The objective of this study is to identify Acute Coronary Syndromes (ACS) patients' specific needs and preferences for depression treatment via in-person or virtual individual interviews to (a) guide MBCT adaptation; and identify…
- Conditions
- Acute Coronary Syndrome, Depression, Myocardial Infarction, Unstable Angina
- Trial name
- NCT03878160
- Testing
- Individual Interview
- Where
- United States
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- Massachusetts General Hospital
Bipolar Depression
Levetiracetam in the Management of Bipolar Depression
A 6-week outpatient, double-blind, placebo-controlled, add-on trial to investigate the effects of levetiracetam on depressive symptoms in bipolar depressed patients.
- Trial name
- NCT00566150
- Testing
- Levetiracetam
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Yale University
Respiratory Insufficiency, Depression
Behavioral Activation-Rehabilitation to Improve Depressive Symptoms & Physical Function After Acute Respiratory Failure
More and more people are surviving after receiving life support for respiratory failure in the intensive care unit, but these patients often experience problems with depression and physical functioning that lead to reduced…
- Conditions
- Respiratory Insufficiency, Depression, Rehabilitation, Critical Care
- Trial name
- BEHAB (NCT03431493)
- Testing
- Behavioral Activation - Rehabilitation
- Where
- United States
- Volunteers
- 52 people
- Sponsor
- Johns Hopkins University
Depression
Ketamine as a Rapidly-Acting Antidepressant in Depressed Emergency Department Patients
Investigators will conduct a trial to evaluate the use of Ketamine as an alternate treatment for people with Major Depressive Disorder.
- Trial name
- NCT02106325
- Testing
- Ketamine, Diphenhydramine
- Where
- 2 sites in United States
- Volunteers
- 21 people
- Sponsor
- NYU Langone Health
Bipolar Disorder, Bipolar Depression
Quetiapine XR Versus Sertraline in Acute Bipolar Depression as add-on Therapy
Prospective, open-label, controlled (active comparator), randomized study of 8 weeks follow-up for the evaluation of the efficacy of extended release quetiapine (quetiapine XR) versus Sertraline in addition to previous mood…
- Trial name
- NCT00857584
- Testing
- Extended release quetiapine (quetiapine XR), Sertraline, adequate mood stabilizer
- Where
- 4 sites in Spain
- Volunteers
- 27 people
- Sponsor
- AstraZeneca
Cardiovascular Diseases, Acute Coronary Syndrome
MBCT Via Group Videoconferencing for Acute Coronary Syndrome Patients With Depressive Symptoms: A Pilot RCT
The aim of this study is to establish, in a pilot RCT (approx. N=50 participants) with a time- and attention-matched health enhancement control, (a) the feasibility of the recruitment procedures (screening, eligibility…
- Conditions
- Cardiovascular Diseases, Acute Coronary Syndrome, Depression
- Trial name
- NCT04799899
- Testing
- Adapted MBCT, Cardiac Health Enhancement
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Massachusetts General Hospital
Bipolar Depression
Ceftriaxone in the Management of Bipolar Depression
We aim to study the efficacy of intravenous ceftriaxone in a four-week, inpatient, placebo-controlled, double-blind study, as an augmentation therapy in patients with bipolar disorder, currently depressed, who have failed to…
- Trial name
- NCT00566111
- Testing
- ceftriaxone, Saline solution
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Yale University
Stress Disorders, Traumatic, Stress Disorders, Traumatic, Acute
Researching Resiliency in Stressful Experiences (RISE) Program for Men Leaving Incarceration
The investigators are conducting a randomized controlled trial to assess the impact of Resiliency in Stressful Experiences (RISE) - a comprehensive trauma-based program for young men releasing from a southeastern state's prisons.
- Conditions
- Stress Disorders, Traumatic, Stress Disorders, Traumatic, Acute, Depressive Symptoms, Anxiety
- Trial name
- NCT04785677
- Testing
- Resiliency in Stressful Experiences (RISE) Program
- Where
- United States
- Volunteers
- 403 people
- Sponsor
- Florida State University
Acute Myocardial Infarction
CARISMA : Cardiac Arrhythmias and Risk Stratification After MyoCardial Infarction
The purpose of this study is to assess the incidence of tachy- and bradyarrhythmic episodes in patients with acute myocardial infarction with depressed ventricular function and to determine the predictive value of several…
- Trial name
- NCT00145119
- Where
- Netherlands
- Volunteers
- 312 people
- Sponsor
- Medtronic Cardiac Rhythm and Heart Failure
Inflammatory Bowel Diseases, Depressive Episode
Risk of Mental Health Conditions in Children and Young Adults With Inflammatory Bowel Disease and Influence on Health
This study is a large population-based analysis in the United Kingdom (UK) using routine primary care data to investigate the impacts on quality-of-life outcomes and use of healthcare services in people aged 5 - 25 years…
- Conditions
- Inflammatory Bowel Diseases, Depressive Episode, Recurrent Depressive Disorder, Anxiety Disorder
- Trial name
- NCT05206734
- Testing
- No specific intervention
- Where
- United Kingdom
- Volunteers
- 19,469 people, healthy volunteers welcome
- Sponsor
- Momentum Data
Anti-Psychotic, Management of Manifestations of Psychotic Disorders
Assessment of Intra-subject Variability in the Bioavailability of Chlorpromazine Hydrochloride
Cycle Pharmaceuticals Ltd. (Cycle) is developing an oral tablet formulation of Chlorpromazine Hydrochloride and intends to conduct bioequivalence trials to demonstrate its similarity to the RLD.
- Conditions
- Anti-Psychotic, Management of Manifestations of Psychotic Disorders, Treatment of Schizophrenia, Control Nausea and Vomiting
- Trial name
- NCT02943213
- Testing
- Chlorpromazine Hydrochloride
- Where
- South Africa
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Cycle Pharmaceuticals Ltd.
Bipolar Depression, Suicidal Ideas
Sequential Therapy for the Treatment of Severe Bipolar Depression.
NeuroRx is developing NRX-101, a fixed-dose combination oral capsule composed of d-cycloserine (DCS) and lurasidone for the maintenance of remission from Severe Bipolar Depression with Acute Suicidal Ideation (C-SSRS level 4 or…
- Conditions
- Bipolar Depression, Suicidal Ideas, Suicidal Ideation, Suicide, Attempted
- Trial name
- STABIL-B (NCT02974010)
- Testing
- NRX-101 Oral Capsule, Lurasidone Oral Capsule, Ketamine Intravenous Infusion
- Where
- 4 sites in United States
- Volunteers
- 22 people
- Sponsor
- NeuroRx, Inc.